Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BSS Plus · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| NGOIS | EXPERIMENTAL | - |
| BSS Plus | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Next Generation Ophthalmic Irrigating Solution (NGOIS) | DRUG | Volume sufficient to irrigate adequately during cataract surgery |
| BSS Plus | DRUG | Volume sufficient to irrigate adequately during cataract surgery |
Inclusion Criteria: * Cataract present. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * As per age requirements. * Other protocol-defined exclusion criteria may apply.
BSS Plus is an ophthalmic irrigating solution used during cataract surgery. It is developed by Alcon Inc. and is in Phase 3 clinical development for the treatment of cataract. The solution is intended to maintain the health of ocular tissues during surgical procedures.
BSS Plus is developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is a global medical device company specializing in eye care products, including surgical equipment and pharmaceuticals.
BSS Plus is in Phase 3 clinical development. It has completed two Phase 3 trials, one involving 369 adult patients and another involving 18 pediatric patients, both conducted in the United States for cataract surgery. The drug is investigational and not yet approved.
BSS Plus has completed two Phase 3 trials. NCT00333268 evaluated the safety and efficacy of a next generation ophthalmic irrigating solution compared to BSS Plus in 369 cataract patients. NCT00346528 assessed the safety of the same solution compared to BSS Plus in 18 pediatric cataract patients.
BSS Plus is not the same as NGOIS (Next Generation Ophthalmic Irrigating Solution). In clinical trials, NGOIS was the investigational product being compared against BSS Plus, which served as the active control. Both are ophthalmic irrigating solutions used during cataract surgery.